Anti-Programmed Death Ligand 1 Plus Targeted Therapy in Anaplastic Thyroid Carcinoma: A Nonrandomized Clinical Trial

Area of Science:

• Oncology
• Molecular Biology
• Clinical Trials

Background:

• Anaplastic thyroid carcinoma (ATC) is a rare, lethal cancer with limited therapeutic options.
• Current treatments offer poor prognosis, especially for non-BRAF mutated tumors.
• Targeted therapies show promise but require combination strategies for optimal outcomes.

Purpose of the Study:

• To evaluate the efficacy of matched-targeted therapy combined with immune checkpoint inhibitors in patients with ATC.
• To determine if this combination improves overall survival (OS) compared to historical controls.

Main Methods:

• A phase 2, single-center trial enrolled 43 systemic therapy-naive ATC patients.
• Patients received atezolizumab plus targeted therapy based on tumor mutation status: BRAF V600E (cohort 1), RAS/NF1/2 (cohort 2), or non-BRAF/RAS/NF1/2 (cohort 3).
• Primary outcome was median OS for the entire cohort, compared to a historical median OS of 5 months.

Main Results:

• The median OS for all 42 analyzed patients was 19 months, significantly exceeding the historical median.
• Cohort 1 (BRAF V600E) demonstrated the longest median OS at 43 months.
• Median OS varied by cohort: 8.7 months (cohort 2) and 6.21 months (cohort 3).

Conclusions:

• Combination of atezolizumab with matched-targeted therapy significantly improved OS in ATC patients.
• The study met its primary endpoint, demonstrating the benefit of this novel therapeutic approach.
• BRAF V600E mutation status correlated with the most favorable survival outcomes.